BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• 

  Business

  Another GSK Executive Departs as Emma Walmsley Continues to Shape Company Leadership

  Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.

  May 11, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Potential Kickbacks

  Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney’s Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.

  May 11, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Gilead—Down but Not Out?

  You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look.

  May 11, 2018

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca’s Fasenra Fails in a COPD Clinical Trial

  AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.

  May 11, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  White House Prepares to Roll Out Drug Pricing Reform Proposal Package Today

  Today the president is expected to propose what could be sweeping reforms to help lower the cost of those medications for consumers.

  May 11, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Akari CEO Abruptly Resigns Following Abuse of Corporate Credit Card

  For the second time in less than one year, Akari Therapeutics is without a chief executive officer. David Horn Solomon abruptly resigned after being caught using the company credit card for personal purposes.

  May 11, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Advisory Committee Gives Green Light to Akcea Therapeutics Rare Disease Drug Waylivra

  Akcea Therapeutics is preparing for the possible launch of its therapeutic for the treatment of the rare lipid disorder familial chylomicronemia syndrome (FCS) following the thumbs up from a U.S. Food and Drug Administration advisory committee.

  May 11, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Job Trends

  Vyriad to Build Oncolytic Virus Manufacturing Plant in Rochester, Minnesota

  Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.

  May 11, 2018

   · 

  3 min read

   · 

  Mark Terry
• Drug Development

  RxFunction Announces Plans for Long-Term Clinical Trial for walkasins®

  RxFunction, Inc. has announced plans to conduct its first long-term clinical trial of walkasins®, the walk2Wellness study.

  May 11, 2018

   · 

  3 min read
• Biotech Bay

  Genome Surgery for Eye Disease Moves Closer to Reality

  Study published in the journal of the American Academy of Ophthalmology shows that a CRISPR-based treatment can restore retinal function in mice

  May 11, 2018

   · 

  5 min read